MOMA Therapeutics is a biotechnology company engaged in the development of small molecule inhibitors targeting highly dynamic proteins, specifically ATPases, that are critical in various oncology indications. Utilizing their proprietary KNOMATIC™ platform, MOMA aims to tackle challenging cancer-related targets and advance their drug candidates through clinical development, with plans for multiple programs set to enter the clinic in the near future. The company's focus on genetically validated targets positions them to enhance therapeutic responses for patients in need. MOMA Therapeutics values collaboration and resilience within its team, fostering a culture where scientific integrity and teamwork drive the discovery of transformative medicines. Headquartered in Cambridge, MA, MOMA is committed to making a meaningful impact in the field of precision medicine and addressing significant medical needs through its innovative research efforts.